TG Therapeutics Inc (NASDAQ: TGTX) is -0.03% lower on its value in year-to-date trading and has touched a low of $12.93 and a high of $36.84 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TGTX stock was last observed hovering at around $28.53 in the last trading session, with the day’s gains setting it 1.56%.
Currently trading at $30.09, the stock is -3.21% and -2.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.41 million and changing 5.47% at the moment leaves the stock 20.64% off its SMA200. TGTX registered 116.32% gain for a year compared to 6-month gain of 30.20%.
The stock witnessed a -9.83% loss in the last 1 month and extending the period to 3 months gives it a -13.06%, and is -2.56% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.74% over the week and 4.60% over the month.
TG Therapeutics Inc (TGTX) has around 264 employees, a market worth around $4.68B and $264.79M in sales. Fwd P/E is 31.02. Profit margin for the company is -5.42%. Distance from 52-week low is 132.71% and -18.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.23%).
The EPS is expected to grow by 61.90% this year.
TG Therapeutics Inc (TGTX) Top Institutional Holders
The shares outstanding are 155.78M, and float is at 140.09M with Short Float at 18.38%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.69 million shares valued at $243.58 million. The investor’s holdings represent 9.3645% of the TGTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 11.39 million shares valued at $202.6 million to account for 7.7891 of the shares outstanding. The other top investors are STATE STREET CORP which holds 6.7 million shares representing 4.5798% and valued at over $119.12 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 2.5189 of the shares totaling 3.65 million with a market value of $64.85 million.
TG Therapeutics Inc (TGTX) Insider Activity
The most recent transaction is an insider sale by Power Sean A, the company’s CFO. SEC filings show that Power Sean A sold 11,337 shares of the company’s common stock on Jan 03 ’25 at a price of $30.29 per share for a total of $0.34 million. Following the sale, the insider now owns 0.67 million shares.
TG Therapeutics Inc disclosed in a document filed with the SEC on Jan 06 ’25 that Power Sean A (CFO) sold a total of 10,021 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $28.53 per share for $0.29 million. Following the transaction, the insider now directly holds 0.66 million shares of the TGTX stock.
Still, SEC filings show that on Jan 06 ’25, Power Sean A (Officer) Proposed Sale 10,021 shares at an average price of $28.53 for $0.29 million. The insider now directly holds shares of TG Therapeutics Inc (TGTX).
